Want to see SE:ERMA full AI Analyst Report?
ERMA Stock Chart & Stats
kr1.91
-kr0.30(-12.50%)
At close: 4:00 PM EST
kr1.91
-kr0.30(-12.50%)
Day’s Range― - ―
52-Week Rangekr0.21 - kr3.58
Previous CloseN/A
Volume29.79K
Average Volume (3M)4.35K
Market Cap
kr19.02M
Enterprise Valuekr8.12M
Total Cash (Recent Filing)kr17.76M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding74,588,684
10 Day Avg. Volume2,975
30 Day Avg. Volume4,348
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.66
Price to Sales (P/S)48.45
P/FCF Ratio-2.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partnering/licensing Business ModelEnorama’s capital-light model centers on developing proprietary NRT formulations and monetizing them through licensing, milestone payments and royalties. This shifts commercialization costs and distribution risk to partners, enabling the small R&D-focused company to scale product reach without heavy fixed selling infrastructure, a durable advantage for preserving limited internal resources over coming quarters.
Low Financial LeverageNear-zero debt materially lowers interest burden and insolvency risk, giving management flexibility in structuring financings or licensing deals. For a small developer with ongoing R&D spend, low leverage preserves optionality and reduces fixed-cost pressure, making it easier to negotiate partnerships or raise equity without the immediate strain of debt servicing over the next several months.
Prior Positive Gross ProfitAchieving positive gross profit in 2024 demonstrates that Enorama’s formulations can reach acceptable unit economics under certain conditions. This indicates a path to scalable margins if revenue grows and production costs are controlled, providing a structural reason to believe that operating profitability is achievable with successful commercialization or larger partner programs.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow signals ongoing cash burn that will require external financing or partner funding to continue operations. For a small developer, repeated cash deficits pressure runway, increase dilution risk from future equity raises, and constrain investment in development programs, making the company’s operational continuity and project timelines dependent on near-term funding outcomes.
Negative Shareholders' EquityNegative equity reflects accumulated losses and erodes the company’s capital buffer, reducing credibility with lenders and partners and limiting collateral for financing. This structural balance sheet weakness hampers the firm’s ability to withstand shocks, increases dependence on dilutive capital or non-traditional funding sources, and constrains strategic options over the medium term.
Shrinking Revenue & Deteriorating MarginsVery small and declining revenues reduce scale benefits and amplify fixed R&D and overhead per unit of revenue, while worsening margins undermine product economics. This structural trend makes it harder to attract commercial partners or secure favorable royalty terms, and lengthens the timeline to self-sustaining profitability absent successful licensing or significant revenue inflection.
ERMA FAQ
What was Enorama Pharma AB’s price range in the past 12 months?
Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.58 in the past 12 months.
What is Enorama Pharma AB’s market cap?
Enorama Pharma AB’s market cap is kr19.02M.
When is Enorama Pharma AB’s upcoming earnings report date?
Enorama Pharma AB’s upcoming earnings report date is Aug 19, 2026 which is in 37 days.
How were Enorama Pharma AB’s earnings last quarter?
Enorama Pharma AB released its earnings results on May 20, 2026. The company reported -kr0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.17.
Is Enorama Pharma AB overvalued?
According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued.
Does Enorama Pharma AB pay dividends?
Enorama Pharma AB does not currently pay dividends.
What is Enorama Pharma AB’s EPS estimate?
Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enorama Pharma AB have?
Enorama Pharma AB has 74,588,684 shares outstanding.
What happened to Enorama Pharma AB’s price movement after its last earnings report?
Enorama Pharma AB reported an EPS of -kr0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 23.333%.
Which hedge fund is a major shareholder of Enorama Pharma AB?
Currently, no hedge funds are holding shares in SE:ERMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.